Hungarian drugs manufacturer Richter Gedeon anticipates its development to be spurred by operations in Central and Eastern Europe, including those in Romania, given that the situation on the Hungarian market will remain difficult over the next few years, according to Reuters news agency. "Conditions on the domestic market will be difficult in the coming few years, and there is a slim chance that the negative trend affecting the company's activity in Hungary will be reversed," Richter Gedeon's CEO, Erik Bogsch, told Vilaggzdasag publication. Bogsch said that, under the circumstances, the share of Hungarian sales in the overall revenues would continue to go down. He added that Hungary was an exception in Central and Eastern Europe, anticipating that the high development rate in Russia, Poland and Romania would be the sales drivers for the company's main products.
Pentru alte știri, analize, articole și informații din business în timp real urmărește Ziarul Financiar pe WhatsApp Channels
